AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products.
Flawless balance sheet with poor track record.
Share Price & News
How has AnGes's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AJW's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AJW exceeded the German Biotechs industry which returned -1.9% over the past year.
Return vs Market: AJW exceeded the German Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is AnGes's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is AnGes undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AJW's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AJW's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AJW is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AJW is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AJW's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AJW is overvalued based on its PB Ratio (6.1x) compared to the DE Biotechs industry average (3.1x).
How is AnGes forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AnGes has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine AnGes's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- AnGes competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has AnGes performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AJW has high quality earnings.
Growing Profit Margin: AJW is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AJW is unprofitable, and losses have increased over the past 5 years at a rate of -0.4% per year.
Accelerating Growth: Unable to compare AJW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AJW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: AJW has a negative Return on Equity (-27.43%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is AnGes's financial position?
Financial Position Analysis
Short Term Liabilities: AJW's short term assets (¥11.9B) exceeds its short term liabilities (¥341.0M)
Long Term Liabilities: AJW's short term assets (¥11.9B) exceeds its long term liabilities (27.0M)
Debt to Equity History and Analysis
Debt Level: AJW is debt free.
Reducing Debt: AJW has not had any debt for past 5 years.
Inventory Level: AJW has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if AJW's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AJW has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AJW has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.5% each year
What is AnGes's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AJW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AJW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AJW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AJW's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AJW's dividend in 3 years as they are not forecast to pay a notable one for the German market.
What is the CEO of AnGes's salary, the management and board of directors tenure and is there insider trading?
Average board tenure
Ei Yamada (69yo)
Mr. Ei Yamada, Ph.D. has been the President and Chief Executive Officer of AnGes MG Inc since September 2002. Mr. Yamada has been the Chief Executive Officer at AnGes Euro Limited since June 2002 and AnGes ...
Board Age and Tenure
Experienced Board: AJW's board of directors are considered experienced (6.1 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.
Ei Yamada (69yo)
- Tenure: 17.2yrs
Ei Yamada (69yo)
- Tenure: 17.2yrs
Tadashi Hishida (85yo)
- Tenure: 17.4yrs
- Tenure: 1.7yrs
Akihiro Narimatsu (72yo)
- Tenure: 6.7yrs
Junichi Komamura (69yo)
- Tenure: 7.7yrs
Norikazu Eiki (71yo)
- Tenure: 5.5yrs
- Tenure: 2.7yrs
Standing Corporate Auditor
- Tenure: 2.7yrs
AnGes, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AnGes, Inc.
- Ticker: AJW
- Exchange: DB
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥78.837b
- Listing Market Cap: JP¥656.136m
- Shares outstanding: 106.97m
- Website: https://www.anges.co.jp
Number of Employees
- AnGes, Inc.
- Saito Bio-Incubator
- 1st Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4563||TSE (The Tokyo Stock Exchange)||Yes||Common Stock||JP||JPY||Sep 2002|
|AJW||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2002|
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatmen ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/11/21 20:59|
|End of Day Share Price||2019/11/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.